These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 624024)

  • 41. [Pathogenesis of hyperparathyroidism in renal failure].
    Galus K
    Pol Arch Med Wewn; 1974 Aug; 52(2):195-203. PubMed ID: 4605842
    [No Abstract]   [Full Text] [Related]  

  • 42. Control of secondary hyperparathyroidism by vitamin D derivatives.
    Drüeke TB
    Am J Kidney Dis; 2001 Jan; 37(1 Suppl 2):S58-61. PubMed ID: 11158863
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Secondary hyperparathyroidism: especially in chronic renal failure (author's transl)].
    Tomita A
    Horumon To Rinsho; 1981 Nov; 29(11):1343-9. PubMed ID: 7341000
    [No Abstract]   [Full Text] [Related]  

  • 44. [Phosphate binding therapy].
    Kinugasa E; Ito H
    Nihon Rinsho; 2004 May; 62 Suppl 5():379-83. PubMed ID: 15197949
    [No Abstract]   [Full Text] [Related]  

  • 45. Hyperparathyroidism in patients on chronic hemodialysis.
    Savoy GM; Yium JJ; Jordan PH; Guinn GA
    Am J Surg; 1973 Dec; 126(6):755-7. PubMed ID: 4758794
    [No Abstract]   [Full Text] [Related]  

  • 46. Vitamin D compounds in chronic kidney disease.
    Scissors K
    Ann Intern Med; 2008 Jun; 148(12):969; author reply 970. PubMed ID: 18559844
    [No Abstract]   [Full Text] [Related]  

  • 47. Activated vitamin D sterols in kidney disease.
    Thadhani R
    Lancet; 2008 Feb; 371(9612):542-4. PubMed ID: 18280316
    [No Abstract]   [Full Text] [Related]  

  • 48. Vitamin D compounds in chronic kidney disease.
    Coyne DW
    Ann Intern Med; 2008 Jun; 148(12):969-70; author reply 970. PubMed ID: 18559843
    [No Abstract]   [Full Text] [Related]  

  • 49. Falecalcitriol for conventional vitamin D therapy-resistant secondary hyperparathyroidism in a continuous ambulatory peritoneal dialysis patient.
    Tokunaga M; Tamura M; Kabashima N; Serino R; Shibata T; Matsumoto M; Miyamoto T; Miyazaki M; Furuno Y; Takeuchi M; Abe H; Okazaki M; Otsuji Y
    Clin Nephrol; 2008 May; 69(5):393-4. PubMed ID: 18538106
    [No Abstract]   [Full Text] [Related]  

  • 50. Effects of secondary hyperparathyroidism treatments on blood pressure and lipid levels in chronic renal failure patients.
    Saatci U; Akman B; Akcay A; Ozdemir FN; Budak B; Haberal M
    Transplant Proc; 2002 Sep; 34(6):2041-3. PubMed ID: 12270307
    [No Abstract]   [Full Text] [Related]  

  • 51. Is administration of vitamin D metabolite needed for the treatment of secondary hyperparathyroidism at the predialytic stage?
    Okada K; Takahashi S; Yanai M; Maejima M; Nagura Y; Hatano M
    Nephron; 1991; 58(4):492-3. PubMed ID: 1922623
    [No Abstract]   [Full Text] [Related]  

  • 52. Medical control of secondary hyperparathyroidism: we're not there yet.
    Goodman WG
    Kidney Int; 2004 Jan; 65(1):335-6. PubMed ID: 14675068
    [No Abstract]   [Full Text] [Related]  

  • 53. Hyperparathyroidism before and after renal transplantation: an introduction.
    Malm OJ
    Scand J Urol Nephrol Suppl; 1977; (42):125-6. PubMed ID: 356190
    [No Abstract]   [Full Text] [Related]  

  • 54. Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure.
    Llach F; Yudd M
    Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S3-12. PubMed ID: 9808139
    [No Abstract]   [Full Text] [Related]  

  • 55. Recent developments in the management of secondary hyperparathyroidism.
    Goodman WG
    Kidney Int; 2001 Mar; 59(3):1187-201. PubMed ID: 11231381
    [No Abstract]   [Full Text] [Related]  

  • 56. The D-lemia for preventing secondary hyperparathyroidism in chronic kidney disease.
    Holick MF
    Endocr Pract; 2008; 14(1):6-9. PubMed ID: 18238735
    [No Abstract]   [Full Text] [Related]  

  • 57. [Advances in blood purification medicine in 2008].
    Shigematsu T; Negi S; Sakaguchi T; Oda H; Ohura M
    Nihon Jinzo Gakkai Shi; 2009; 51(1):27-32. PubMed ID: 19238905
    [No Abstract]   [Full Text] [Related]  

  • 58. Introduction: emerging therapies derived from the molecular pathogenesis of secondary hyperparathyroidism in ESRD patients.
    Quarles LD
    Adv Ren Replace Ther; 2002 Jul; 9(3):153-8. PubMed ID: 12203196
    [No Abstract]   [Full Text] [Related]  

  • 59. Spontaneous remission of secondary hyperparathyroidism in patient receiving regular dialysis.
    Ahmad R; Raichura N; Goldsmith HJ
    Br Med J (Clin Res Ed); 1982 Feb; 284(6314):469. PubMed ID: 6800496
    [No Abstract]   [Full Text] [Related]  

  • 60. [Prevention and treatment of secondary hyperparathyroidism in CKD].
    Gueiros JE; Hernandes FR; Karohl C; Jorgetti V;
    J Bras Nefrol; 2011; 33(2):197-204. PubMed ID: 21789441
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.